ArticleCell death and differentiation2026
NLRX1 is a critical neutrophil checkpoint modulating ferroptosis and suppressing NETosis to attenuate joint damage in arthritis.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutrophil extracellular traps (NETs) are key drivers of inflammation and tissue damage in rheumatoid arthritis (RA), yet the mechanisms that restrain NETs overproduction remain unclear. Here, we identify the mitochondrial NOD-like receptor NLRX1 as a critical checkpoint limiting NETs production. The expression of NLRX1 is dysregulated in RA patients. NLRX1 deficiency leads to a profound expansion of the neutrophil population, and neutrophil-specific NLRX1 deficiency results in broad production of cytokines, chemokines, autoantibodies and complement accompanied by markedly accelerated arthritis, exaggerated NETs formation, and enhanced joint damage. Single-cell RNA sequencing reveals that NLRX1 restrains a Padi4-high neutrophil population that is central to NETosis. Mechanistically, NLRX1 deficiency promotes sustained TRAF6-NF-κB signaling and activates the NRF2-mediated oxidative defense pathway, which confers ferroptosis resistance to extend neutrophil lifespan and provides a prolonged temporal window for continuous NETs formation. NLRX1-knockdown cells exhibit increased NETs release, with a more ordered periodic distribution of myeloperoxidase (MPO) along the citrullinated histone H3 (CitH3)-decorated DNA backbone forming the typical 'beads-on-a-string' pattern, suggesting enhanced structural organization of NETs. NETs, known to directly degrade bone matrix through proteolytic enzymes, also promote TNFα production, with the cytokine enriched on NETs structures. TNFα in turn stimulates synovial macrophages to express the pro-osteoclastic factor RANKL, thereby fueling bone destruction. Pharmacological activation of the NLRX1 checkpoint attenuates osteoclast differentiation and joint damage. Collectively, these findings unveil the new role of NLRX1 in regulating neutrophil ferroptosis and NETs production and its potential as a therapeutic target for mitigating cartilage and bone damage in RA.
Identifiers
42778685What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.